Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

globenewswire.com
AMGN Mentioned as a key company in the Atopic Dermatitis Market, indicating involvement in the eczema treatment space. No specific drug or trial performance is detailed. PFE Listed as a key company in the Atopic Dermatitis Market and Pipeline Insight reports, suggesting involvement in eczema drug development. No specific performance data is provided. LLY AZN Mentioned as a key company in the Atopic Dermatitis Pipeline Insight report, suggesting involvement in eczema drug development. No specific details on its pipeline or performance are provided. BMY NVS Mentioned as a key company in the Atopic Dermatitis Pipeline Insight report, suggesting its participation in the eczema therapeutic area. No specific drug or trial performance is detailed. SNY Listed as a key company in both the Atopic Dermatitis Market and Pipeline Insight reports, indicating involvement in eczema treatments. No specific performance details are provided. GSK Mentioned as a key company in the Atopic Dermatitis Pipeline Insight report, suggesting involvement in eczema drug development. No specific performance data is provided. UCB Listed as a key company in both the Atopic Dermatitis Market and Pipeline Insight reports, indicating its participation in the eczema therapeutic area. No specific drug or trial performance is detailed. ARQT Mentioned as a key company in both the Atopic Dermatitis Market and Pipeline Insight reports, suggesting involvement in eczema drug development. No specific performance data is provided. REGN Although not explicitly named, Regeneron is a major player in atopic dermatitis with Dupixent, and its involvement is implied by the general market discussion. No specific performance data is provided. INCY While not explicitly named, Incyte is involved in eczema research and development, and its presence is implied by the broad discussion of pipeline acceleration. No specific performance data is provided. ABBV BIIB While not explicitly named, Biogen's focus on immunology suggests potential involvement in the eczema therapeutic area. No specific performance data is provided. MRK Mentioned as a key company in the Atopic Dermatitis Market, indicating its participation in the eczema therapeutic area. No specific drug or trial performance is detailed. JNJ VNDA Mentioned as a key company in the Atopic Dermatitis Pipeline Insight report, indicating involvement in eczema drug development. No specific performance data is provided. RAPT Listed as a key company in the Atopic Dermatitis Pipeline Insight report, suggesting involvement in eczema drug development. No specific performance data is provided. CHAI ONON Listed as a key company in the Atopic Dermatitis Pipeline Insight report, suggesting involvement in eczema drug development. No specific performance data is provided. ION ASMB Mentioned as a key company in the Atopic Dermatitis Market and Pipeline Insight reports, indicating involvement in eczema drug development. No specific performance data is provided. CRVS Mentioned as a key company in the Atopic Dermatitis Market, suggesting involvement in the eczema therapeutic area. No specific drug or trial performance is detailed. APG Listed as a key company in the Atopic Dermatitis Market, indicating involvement in eczema drug development. No specific performance data is provided. KSCP Although not explicitly named, Karyopharm's focus on inflammatory diseases suggests potential involvement in the eczema market. No specific performance data is provided. KYMR Although not explicitly named, Kymera's focus on immunology suggests potential involvement in the eczema therapeutic area. No specific performance data is provided. XBI IBB ADSK The article mentions 'DelveInsight's Pharma Competitive Intelligence Service' which could involve data analytics and software solutions, potentially benefiting companies like Autodesk. However, no direct link is made. CDNS The article's mention of complex data analysis and clinical trial benchmarking might indirectly benefit companies providing such technological solutions, like Cadence. No direct link is made. SNPS The article's discussion of advanced therapies and data analysis in drug development could indirectly benefit companies like Synopsys that provide design and verification tools. No direct link is made.

New York, USA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Eczema, a chronic inflammatory skin condition, significantly impacts patients’ quality of life through persistent itching and irritation. The market is being driven by growing awareness, increasing diagnosis rates, and the expanding availability of advanced therapies. The introduction of biologics and targeted treatments has redefined disease management by addressing immune mechanisms more precisely. These innovations are fueling strong market momentum and shaping a more dynamic therapeutic landscape.

DelveInsight’s ' Eczema Pipeline Insight 2025' report provides comprehensive global coverage of pipeline therapies for eczema across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the eczema domain.

Eczema Clinical Trial Analysis Summary

Request a sample and discover the recent advances in eczema drugs @ Eczema Pipeline Report

What is Eczema?

Eczema, also known as atopic dermatitis, is the most common type of dermatitis. Both genetic and environmental factors influence its development. While eczema is most frequently observed in children, it can also affect adults. Individuals with eczema typically experience dry, itchy skin that is susceptible to infections. The condition is often referred to as the “itch that rashes” because scratching or rubbing the dry skin can trigger a rash. The cornerstone of eczema management is maintaining skin hydration, with topical steroids used to control flare-ups. The lifetime prevalence of atopic dermatitis is estimated at 15–30% in children and 2–10% in adults, with around 60% of cases appearing within the first year of life. Eczema occurs more often in rural than urban settings, highlighting the role of lifestyle and environmental factors in its development.

Find out more about eczema drugs @ Eczema Treatment

A snapshot of the Pipeline Eczema Drugs mentioned in the report:

Learn more about the emerging eczema therapies @ Eczema Clinical Trials

Recent Developments in Eczema Treatment Space

Scope of the Eczema Pipeline Report

Dive deep into rich insights for new eczema treatments, visit @ Eczema Drugs

Table of Contents

For further information on the eczema pipeline therapeutics, reach out @ Eczema Therapeutics

Related Reports

Eczema Epidemiology Forecast

Eczema Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted eczema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Hand Eczema Market

Chronic Hand Eczema Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic hand eczema companies, including LEO Pharma, Japan Tobacco, Asana Biosciences, among others.

Chronic Hand Eczema Pipeline

Chronic Hand Eczema Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic hand eczema companies, including LEO Pharma, Japan Tobacco, Asana Biosciences, among others.

Atopic Dermatitis Market

Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key atopic dermatitis companies including Arcutis Biotherapeutics, Amgen, Kyowa Kirin, Dermavant Sciences, Cara Therapeutics, Pfizer, Arena Pharmaceuticals, BioMimetix, Eli Lilly and Company, Aldeyra Therapeutics, Inc., Hangzhou Yirui Pharmaceutical Technology Co., Ltd, LEO Pharma, Corvus Pharmaceuticals, Inc., Brexogen Inc., Sanofi, Shaperon, UCB Pharma, Q32 Bio Inc., Akeso, Apogee Therapeutics, Inc., Allakos Inc., Biosion, Inc., among others.

Atopic Dermatitis Clinical Trial Analysis

Atopic Dermatitis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key atopic dermatitis companies, including Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others. Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, Evommune, Inc., Fresh Tracks Therapeutics, Biosion, Chia Tai Tianqing Pharmaceutical, Reistone Biopharma Company Limited, JW Pharmaceutical, Oneness Biotech, Alphyn Biologics, selectION, UNION Therapeutics, Ichnos Scien, among others.

DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Pharmaceutical Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Connect with us at LinkedIn